Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

3.

Combination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity.

Heudebert GR, Van Ruiswyk J, Hiatt J, Schectman G.

Arch Intern Med. 1993 Aug 9;153(15):1828-37.

PMID:
8333817
4.

The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease.

Ho KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D.

Am J Cardiovasc Drugs. 2006;6(6):383-91.

PMID:
17192128
5.
6.

Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.

Stewart BF, Brown BG, Zhao XQ, Hillger LA, Sniderman AD, Dowdy A, Fisher LD, Albers JJ.

J Am Coll Cardiol. 1994 Mar 15;23(4):899-906.

7.
8.

Managing dyslipidemia in the high-risk patient.

Stein EA.

Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. Review.

PMID:
11900720
9.

Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.

Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.

Clin Ther. 2008 Jan;30(1):84-97. doi: 10.1016/j.linthera.2008.01.013.

PMID:
18343245
10.
11.

Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.

Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D.

Curr Med Res Opin. 2005 Sep;21(9):1389-99.

PMID:
16197657
12.
13.

Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study.

Kim HS, Wu Y, Lin SJ, Deerochanawong C, Zambahari R, Zhao L, Zhang Q, Yan P.

Curr Med Res Opin. 2008 Jul;24(7):1951-63. doi: 10.1185/03007990802138731 . Epub 2008 Jun 10.

PMID:
18547466
14.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
16.

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.

Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E; Ezetimibe Study Group.

Am Heart J. 2004 Sep;148(3):447-55.

PMID:
15389231
17.
18.

Management of hypercholesterolaemia in postmenopausal women.

Davidson MH, Maki KC, Karp SK, Ingram KA.

Drugs Aging. 2002;19(3):169-78. Review.

PMID:
12027776
19.

Management of dyslipidemia in the high-risk patient.

Stein EA.

Am Heart J. 2002 Dec;144(6 Suppl):S43-50. Review.

PMID:
12486415
20.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

PMID:
15358046

Supplemental Content

Support Center